<DOC>
	<DOCNO>NCT00423358</DOCNO>
	<brief_summary>This study recruit individual rheumatoid arthritis ( RA ) low vitamin D concentration . Subjects dose vitamin D placebo one year . Primary outcome change bone turnover marker , additionally , bone mineral density parameter RA status evaluate throughout study .</brief_summary>
	<brief_title>Treatment Hypovitaminosis D Rheumatoid Arthritis</brief_title>
	<detailed_description>Osteoporosis twice common people rheumatoid arthritis ( RA ) , compare age gender-matched control [ 1 , 2 ] . Hypovitaminosis D contribute osteoporosis pathogenesis decrease calcium absorption , lead decline serum ionized calcium , rise parathyroid hormone level upregulation osteoclast activity , leading loss calcium skeleton . Hypovitaminosis D also common patient rheumatoid arthritis [ 3-5 ] , make appeal target potentially improve health RA osteoporosis . Vitamin D theoretic potential modulate RA disease activity , base presence vitamin D receptor lymphocytes , macrophage , chondrocytes , synovial cell [ 6 ] . Vitamin D , give bioactive metabolite 1,25 ( OH ) 2D , ameliorate disease activity murine model RA [ 7 , 8 ] . However , study evaluate effect vitamin D RA disease activity human . Two three month open-label study report vitamin D reduce RA disease activity [ 9 ] pain level [ 10 ] . By contrast , eight-week open-label study [ 11 ] report reduction swell joint count , inflammatory marker cytokine level vitamin D therapy . The double-blind , placebo-controlled trial publish thus far [ 12 ] find significant effect vitamin D RA disease activity , limited lack hypovitaminosis D criterion study entry . Indeed , baseline subject ' mean 25 ( OH ) D level indicate vitamin D repletion , potentially explain null effect vitamin D RA disease activity . Three study evaluate effect vitamin D bone mineral density ( BMD ) patient RA [ 13-15 ] . Researchers [ 14 ] randomize 96 subject RA vitamin D ( 500 IU/day ) calcium ( 1000 mg/day ) placebo two year ; vitamin D calcium therapy modestly increase BMD spine hip . In another study [ 15 ] , 20 subject randomize daily calcium 1 Î±-hydroxyvitamin D 24 month experience similar decline radius spine BMD compare 15 control [ 15 ] . Likewise , vitamin D calcium prevent bone loss prospective cohort study patient RA [ 13 ] . However , none study require hypovitaminosis D entry criterion , vitamin D repletion 25 ( OH ) D level &gt; 32 ng/ml evaluate [ 13 , 14 ] achieve [ 15 ] , low dos vitamin D administer , potentially limit skeletal benefit therapy . We hypothesize correction hypovitaminosis D subject RA would decrease parathyroid hormone ( PTH ) , increase BMD , improve functional capacity down-regulate inflammatory cytokine production , thereby diminish disease activity . Vitamin D inexpensive widely available . If proven beneficial , vitamin D might become mainstay therapy subject RA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Avitaminosis</mesh_term>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Rheumatology Bisphosphonate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>hypovitaminosis D</keyword>
	<keyword>bone turnover</keyword>
	<keyword>ergocalciferol</keyword>
</DOC>